A majority of patients with systemic lupus erythematosus achieve prolonged remission when treated with hydroxychloroquine at ...

The following is a summary of “Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis,” published in the February 2025 ...

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

Tailoring rituximab treatment among patients with pemphigus based on the presence of predictors of early relapse reduced relapse rates at 12 months.

Brukinsa plus R-CHOP demonstrated high efficacy and durable responses in double-expressor lymphoma, with manageable safety, supporting further phase 3 trials.

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

For patients with active lupus nephritis, obinutuzumab plus standard therapy is more efficacious than standard therapy alone.

Brittany Lancellotti, DVM, DACVD, broke down the treatments for canine allergic dermatitis, including through song, in her lecture at WVC 2025 ...

Immunoglobulin G hypogammaglobulinemia was found in 44.7% of patients with acute exacerbations of COPD receiving triple ...